key: cord-0963530-if566vby
authors: Thompson, Mark G; Cowling, Benjamin J
title: How repeated influenza vaccination effects might apply to COVID-19 vaccines
date: 2022-04-28
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(22)00162-x
sha: 81ca4da750a4485a997851a7f5c69e18c4176cc8
doc_id: 963530
cord_uid: if566vby

nan

Many of the current questions on the public health and research aspects of the future of COVID-19 vaccines and vaccine strategies have been topics of research and debate in the influenza vaccine literature for decades. Here, we describe how the lessons learned from the study of repeated influenza vaccinations might apply to the evaluation of COVID-19 vaccines, and the prospect of future seasonal or periodic booster vaccinations.

There are many differences between COVID-19 and influenza vaccines in their design and manufacturing, immunological context, and effectiveness in preventing disease. Nonetheless, since both the SARS-CoV-2 and influenza viruses are constantly evolving and can escape vaccine-induced immunity, and since protection from both vaccines declines with time, 1 it can be expected that, similar to influenza vaccines, additional COVID-19 vaccine doses will be needed to maintain optimal levels of protection. The frequency, timing, and groups prioritised for further COVID-19 vaccine doses will depend on multiple factors, including the magnitude of vaccine effectiveness waning against the most severe COVID-19 outcomes, the differential effect of vaccine effectiveness waning on immunocompromised people and older adults, and the cost-effectiveness of different vaccine strategies.

Data on influenza vaccines suggests that repeated vaccinations in an individual might ultimately result in a blunted immune response, declines in vaccine effectiveness, and a possibly reduced duration of protection. In multiseason studies, immunogenicity after influenza vaccination and vaccine effectiveness against influenza-associated medical care were both often lower among people vaccinated in the previous and current season compared with those vaccinated in the current season only. 2 In the few studies that were able to gather vaccine records for 4-6 previous years, immunogenicity and vaccine effectiveness were highest among those with no or few previous vaccinations and lowest among those frequently vaccinated. 2 The underlying mechanisms through which previous vaccinations can affect the effectiveness of subsequent vaccinations in an individual are unclear, but two theories are widely discussed in the influenza literature.

According to the antigenic distance hypothesis, the effect of previous vaccinations is established by the antigenic distance between the vaccine antigens in the previous dose versus the subsequent booster dose and the antigenic distance between the vaccine antigen and the circulating virus. The blunting of influenza vaccine effectiveness by previous influenza vaccination has been the most pronounced when the vaccine antigen was unchanged, but an antigenically distinct virus became the predominant circulating strain. 3 Although third COVID-19 mRNA vaccine doses produce the same level of vaccine effectiveness as achieved by a second mRNA dose, 1 the antigenic distance hypothesis would suggest that COVID-19 vaccine effectiveness after a fourth or fifth vaccine dose might decline if the vaccine antigen is unchanged, and new antigenically distinct variants circulate. The introduction of updated vaccine antigens might overcome preferential antibody responses to an imprinting infection (ie, original antigenic sin) or the effects of a repeatedly administered vaccine antigen, as has been noted with influenza vaccines. 4 The second theory focuses on changes that might occur among people who are unvaccinated compared with those who are repeatedly vaccinated. Since vaccine-induced immunity blocks or reduces the risk of infection, the theory asserts that the percentage of people who are unvaccinated with presumably stronger infection-induced immunity will increase over time (also referred to as the infection block hypothesis). Thus, estimates of COVID-19 vaccine effectiveness will probably decline as the gap in immune protection between people who are repeatedly vaccinated versus those who are unvaccinated declines.

If repeated COVID-19 vaccination leads to blunted vaccine effectiveness or a reduction in protection relative to people who are unvaccinated, findings from new studies comparing different influenza vaccine types and vaccine strategies point to at least four lessons to be learned. First, vaccine effectiveness studies might need to stratify their estimates by those with and without documented previous infection and by the differences in previous vaccination status to disentangle changes in vaccine effectiveness versus changes in population Dr P. Marazzi/Science Photo Library susceptibility over time. This separation has not been feasible in the evaluations of influenza vaccines, but it might be possible in the evaluations of COVID-19 vaccines given widespread virus testing and the improved documentation of infections. Second, the optimal spacing of additional COVID-19 vaccine doses over time deserves much more investigation than it has been given to date. If COVID-19 becomes an endemic virus with seasonal circulation, spacing out COVID-19 vaccine doses at 9-month intervals or 12-month intervals might provide as much protection as more frequent vaccination such as every 6 months. Third, changing the SARS-CoV-2 vaccine antigen will be especially necessary to protect people who are repeatedly vaccinated from new variants, because the focusing of antibody responses toward older strains can be an undesirable consequence of repeated vaccination. 4 Fourth, introducing alternative vaccine types might improve immunogenicity and vaccine effectiveness compared with the repeated use of the same vaccine technology. In one study, older adults who received either a high dose, adjuvanted, or recombinant protein influenza vaccine had a superior serological and cell-mediated immune response compared with older adults who repeatedly received egg-based inactivated vaccines. 5 Research is needed to assess whether systematically alternating COVID-19 vaccine schedules to introduce different vaccine types can improve the effects of the vaccine.

The future of influenza and COVID-19 vaccines are now intertwined. Long-lasting debates surrounding influenza vaccine technologies, dose spacing, and strain composition can inform parallel debates about COVID-19 vaccines. The future of influenza vaccines will be changed by the findings on COVID-19 vaccines as well. Moderately effective inactivated influenza vaccines might be less acceptable to a public who have grown accustomed to highly effective COVID-19 vaccines. New technologies for vaccines, such as mRNA, and the broader availability of second-generation influenza vaccines (eg, high-dose, adjuvanted, and non-eggbased products) could considerably improve the average annual vaccine effectiveness of influenza vaccines. The race to optimise the preventive benefit of both influenza and COVID-19 vaccines benefits everyone. 

Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance -VISION Network, 10 States

Repeated annual influenza vaccination and vaccine effectiveness: review of evidence

Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada

Immune history and influenza virus susceptibility

Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial